<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of inhibiting activated blood coagulation factor XIa was determined in rat models of <z:mp ids='MP_0005048'>thrombosis</z:mp> and hemostasis </plain></SENT>
<SENT sid="1" pm="."><plain>BMS-262084 is an irreversible and selective small molecule inhibitor of factor XIa with an IC(50) of 2.8 nM against human factor XIa </plain></SENT>
<SENT sid="2" pm="."><plain>BMS-262084 doubled the activated thromboplastin time in human and rat plasma at 0.14 and 2.2 microM, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Consistent with factor XIa inhibition, the prothrombin time was unaffected at up to 100 microM </plain></SENT>
<SENT sid="4" pm="."><plain>BMS-262084 administered as an intravenous loading plus sustaining infusion was effective against FeCl(2)-induced <z:mp ids='MP_0005048'>thrombosis</z:mp> in both the vena cava and carotid artery </plain></SENT>
<SENT sid="5" pm="."><plain>Maximum <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight reductions of 97 and 73%, respectively (P&lt;0.05), were achieved at a pretreatment dose of 12 mg/kg+12 mg/kg/h which increased the ex vivo activated thromboplastin time to 3.0 times control </plain></SENT>
<SENT sid="6" pm="."><plain>This dose level also arrested growth of venous and arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> when administered after partial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="7" pm="."><plain>BMS-262084 was most potent in FeCl(2)-induced <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo>, decreasing <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight 38% (P&lt;0.05) at a threshold dose of 0.2 mg/kg+0.2 mg/kg/h </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, doses of up to 24 mg/kg+24 mg/kg/h had no effect on either tissue factor-induced <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> or the ex vivo prothrombin time </plain></SENT>
<SENT sid="9" pm="."><plain>Doses of up to 24 mg/kg+24 mg/kg/h also did not significantly prolong <z:mp ids='MP_0001914'>bleeding</z:mp> time provoked by either puncture of small mesenteric blood vessels, template incision of the renal cortex, or cuticle incision </plain></SENT>
<SENT sid="10" pm="."><plain>These results demonstrate that pharmacologic inhibition of factor XIa achieves antithrombotic efficacy with minimal effects on provoked <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
</text></document>